CD28 expression during lenalidomide immune modulation
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsPearlie Burnette, Jessica M. McDaniel
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods for predicting responsiveness of a subject to treatment with lenalidomide (LEN) by assaying a sample from the subject for surface expression of CD28 on T-cells. Also provided is a method of treating a subject for cancer that involves assaying a sample from the subject for surface expression of CD28 on T-cells and then treating them with LEN if they do not have reduced CD28 surface expression on the T-cells. Also provided is a method for promoting responsiveness of a subject to LEN by administering to the subject a composition that promotes expression of CD28 on the surface of T-cells.
Claims6
A method for treating a subject with myelodysplastic syndrome (MDS), comprising:
- a) assaying a sample from the subject for surface expression of CD28 on CD4+ and/or CD8+ T-cells;
- and
- b) treating the subject with lenalidomide if elevated numbers of CD8+ T-cells in the sample have detectable CD28 surface expression compared to a lenalidomide non-responder control, elevated numbers of CD4+ T-cells in the sample have detectable CD28 surface expression compared to a lenalidomide non-responder control, or a combination thereof.
Dependencies are inferred from the claim text.